B Sautois
Overview
Explore the profile of B Sautois including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sautois B, Denis C
Rev Med Liege
. 2022 Oct;
77(10):609-615.
PMID: 36226398
Androgen-deprivation therapy (ADT), either bilateral orchiectomy or treatment with a gonadotropin-releasing hormone analogue agonist or antagonist, is the mainstay of treatment for advanced prostate cancer. In the metastatic setting, although...
2.
Lambert E, Hollebosch S, Van Praet C, Van Bruwaene S, Duck L, De Roock W, et al.
Acta Clin Belg
. 2021 Nov;
77(6):897-905.
PMID: 34789066
Introduction: Abiraterone acetate + prednisone (AAP) and docetaxel have proven their efficacy in the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) in clinical trials. However, real-world...
3.
Colassin A, Denis C, Hermesse J, Waltregny D, Sautois B
Rev Med Liege
. 2021 Jun;
76(5-6):496-501.
PMID: 34080386
In Belgium, 12 % of patients present with upfront metastatic hormone-naive prostate cancer. Surgical or medical castration has been the only approved treatment for decades. Since 2014, several randomized trials...
4.
Lecocq M, Poncin A, Sautois B
Rev Med Liege
. 2021 Jun;
76(5-6):398-402.
PMID: 34080370
Current recommendations for systemic treatments of head and neck squamous cell carcinoma have been significantly modified with the advent of immunotherapy for a majority of these cancers. Indeed, immune checkpoint...
5.
Piret P, Werenne X, Sautois B, Demez P, Coucke P
Rev Med Liege
. 2014 May;
69 Suppl 1:58-62.
PMID: 24822307
The diagnostic work-up of cervical lymph node metastases from an occult primary tumour in the head and neck region is well established. PET-scan, which was controversial, is nowadays an integral...
6.
Sautois B, Gennigens C
Rev Med Liege
. 2013 Mar;
68(2):94-6.
PMID: 23469490
Docetaxel chemotherapy is a standard treatment for fit men with symptomatic castration-resistant prostate cancer. Unfortunately docetaxel resistant disease will systematically develop and second-line treatment may be appropriate. Until recently no...
7.
Seront E, Rottey S, Sautois B, Kerger J, DHondt L, Verschaeve V, et al.
Ann Oncol
. 2012 Apr;
23(10):2663-2670.
PMID: 22473592
Background: This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after failure of platinum-based therapy....
8.
Gennigens C, Sautois B, Jerusalem G
Rev Med Liege
. 2010 May;
65(4):212-6.
PMID: 20499824
Renal cell carcinoma accounts for 3% of all malignant tumours. Until a few years ago, immunotherapy (interferon and/or interleukin-2) was the only approved option in the metastatic setting. Better knowledge...
9.
Martin M, Demez P, Moreau P, Devillers D, Piret P, Sautois B
Rev Med Liege
. 2010 Mar;
65(1):15-7.
PMID: 20222503
Head and neck cancer represent 5% of all cancer and is often diagnosed at advanced stage. Treatment requires a multidisciplinary approach and relies on surgery, radiotherapy and/or chemotherapy. In locally...
10.
Sautois B, Martin M, Demez P, Piret P, Devillers D, Moreau P
Rev Med Liege
. 2009 Aug;
64(5-6):284-6.
PMID: 19642460
Monoclonal antibodies are now part of the armamentarium available for the treatment of head and neck cancer. Cétuximab, a monoclonal antibody targeting EGFR, improves overall survival as compared with radiotherapy...